title: Bony metastases of anaplastic oligodendroglioma respond to temozolomide.
abstract: BACKGROUND
  Fewer than 30 cases of oligodendroglioma or anaplastic oligodendroglioma metastatic to bone are reported in the literature. Prolonged survival even with therapy is uncommon.
  
  
  METHODS
  We report a case of anaplastic oligodendroglioma metastatic to bone with a dramatic and durable response to temozolomide therapy. A retrospective case review, molecular analysis, and literature search were performed.
  
  
  RESULTS
  The patient presented with a right frontal mass in 1990. Progression led to resection of the lesion in 1995. Histology revealed an anaplastic oligodendroglioma and the tumour was found to have allelic loss of heterozygosity (LOH) of chromosome 1p (1p-). He received standard radiation therapy. In 2000 he developed hip and pelvic pain. A bone scan showed multiple skeletal lesions. Magnetic resonance imaging of the brain showed stability of intracranial disease. Resection of one lesion found metastatic anaplastic oligodendroglioma with identical morphology to the patient's original tumour, including glial fibrillary acidic protein expression. The patient was started on standard temozolomide chemotherapy and celecoxib with prompt pain relief, and rapid normalization of serum alkaline phosphatase. He received a total of 12 cycles of combined therapy with no toxicity and no evidence of progression until increasing pain marked disease recurrence. The patient underwent palliative chemo- and radiation therapy but eventually succumbed.
  
  
  CONCLUSIONS
  Loss of heterozygosity 1p- is associated with prolonged survival in anaplastic oligodendroglioma and may increase the cumulative risk for development of systemic metastases. We speculate that metastases from oligodendroglioma harbouring loss of heterozygosity at chromosome 1p- retain the chemosensitivity of the initial lesion.
authors.affiliation: Division of Neurology, Crolla Family Brain Tumour Research Unit, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Tara
authors.initials: T
authors.lastname: Morrison
authors.forename: Juan M
authors.initials: JM
authors.lastname: Bilbao
authors.forename: Guisheng
authors.initials: G
authors.lastname: Yang
authors.forename: James R
authors.initials: JR
authors.lastname: Perry
mesh_terms: D000328:Adult; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009837:Oligodendroglioma / Q000188:drug therapy*; D012189:Retrospective Studies; D000077204:Temozolomide
chemical_list: D003606:Dacarbazine; D000077204:Temozolomide